Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Carl Zeiss Meditec AG    AFX   DE0005313704

CARL ZEISS MEDITEC AG

(AFX)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

information pursuant : Carl Zeiss Meditec is aiming for the upper end of its revenue forecast for the current year and expects strong earnings

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/16/2019 | 04:20am EDT
JENA/Germany, 16.07.2019. Carl Zeiss Meditec (ISIN: DE0005313704) has achieved revenue of around EUR 1,028 million in the first nine months of fiscal year 2018/19, based on preliminary data. This corresponds to revenue growth of around 11 % vs. the previous year's value of EUR 926.3 million. After adjustment for currency effects1, growth amounted to approximately 9 %.

Earnings before interest and taxes (EBIT) is expected to amount to around EUR 184 million after nine months (previous year: EUR 134.8 million). EBIT margin (EBIT / revenue in %) is approximately 17.9% (previous year: 14.6%). A positive development of the product mix with a higher share of consumables contributed to this increase. Earnings per share grew to around EUR 1.22 (previous year: EUR 0.92).

For fiscal year 2018/19, Carl Zeiss Meditec now expects revenue at the upper end of the previous forecast range of EUR 1,350 to EUR 1,420 million. Due to the strong current trend, EBIT margin is expected to exceed the previous forecast range of 15.0 % to 17.5 %.

From today's point of view and in light of planned strategic investments in research & development, management does not expect a further increase in EBIT margin in the coming fiscal year 2019/20. Carl Zeiss Meditec expects to provide a more precise forecast for fiscal year 2019/20 with publication of fiscal year 2018/19 results by Dec 6, 2019. The nine months quarterly statement for fiscal year 2018/19 will be published on August 9, 2019.

1 Currency-adjusted revenue growth is calculated by converting revenue of the previous year's period with current exchange rates.

Sebastian Frericks
Director Investor Relations
Carl Zeiss Meditec AG
Phone: +49 3641 220-116
Fax:
investors.meditec@zeiss.com

Brief profile

Carl Zeiss Meditec AG (ISIN: DE 0005313704), which is listed on the MDAX and TecDAX of the German stock exchange, is one of the world's leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. The Company offers complete solutions, including implants and consumables, to diagnose and treat eye diseases. The Company creates innovative visualization solutions in the field of microsurgery. With approximately 3,050 employees worldwide, the Group generated revenue of €1,280.9m in fiscal year 2017/18 (to 30 September). The Group's head office is located in Jena, Germany, and it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company's presence in these rapidly developing economies. Around 41 percent of Carl Zeiss Meditec AG's shares are in free float. The remaining approx. 59 percent are held by Carl Zeiss AG, one of the world's leading groups in the optical and optoelectronic industries.

For more information visit our website at: www.zeiss.com/med

Number: 0059-2019-ENG OP

Number of Words: 285
Number of Characters: 1725

Disclaimer

Carl Zeiss Meditec AG published this content on 16 July 2019 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 16 July 2019 08:19:07 UTC

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CARL ZEISS MEDITEC AG
10/10CARL ZEISS MEDITEC AG : Release according to Article 40, Section 1 of the WpHG [..
EQ
10/10CARL ZEISS MEDITEC AG : Correction of a release from 03/06/2019 according to Art..
EQ
10/02CARL ZEISS MEDITEC : achieves significant growth in revenue and profit in fiscal..
EQ
08/12CARL ZEISS MEDITEC : continues strong growth trend after nine months of 2018/19
AQ
08/09EUROPE : Italy leads European shares lower on political uncertainty
RE
08/09GLOBAL MARKETS LIVE : Bayer, Huawei, Airbus, Occidental Petroleum…
08/09CARL ZEISS MEDITEC : continues strong growth trend after nine months of 2018/19
EQ
08/09CARL ZEISS MEDITEC AG : 3rd quarter results
CO
08/02CARL ZEISS MEDITEC AG : Preliminary announcement of the publication of quarterly..
EQ
07/16INFORMATION PURSUANT : Carl Zeiss Meditec is aiming for the upper end of its rev..
PU
More news
Financials (EUR)
Sales 2019 1 459 M
EBIT 2019 272 M
Net income 2019 169 M
Finance 2019 665 M
Yield 2019 0,65%
P/E ratio 2019 54,0x
P/E ratio 2020 46,1x
EV / Sales2019 5,87x
EV / Sales2020 5,43x
Capitalization 9 230 M
Chart CARL ZEISS MEDITEC AG
Duration : Period :
Carl Zeiss Meditec AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CARL ZEISS MEDITEC AG
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 10
Average target price 92,83  €
Last Close Price 103,10  €
Spread / Highest target 1,36%
Spread / Average Target -9,96%
Spread / Lowest Target -20,5%
EPS Revisions
Managers
NameTitle
Ludwin Monz President & Chief Executive Officer
Michael Kaschke Chairman-Supervisory Board
Justus Felix Wehmer Chief Financial Officer
Markus Guthoff Member-Supervisory Board
Cornelia Grandy Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
CARL ZEISS MEDITEC AG51.10%10 212
THERMO FISHER SCIENTIFIC25.37%112 357
DANAHER CORPORATION33.23%98 559
INTUITIVE SURGICAL, INC.10.72%61 112
BOSTON SCIENTIFIC CORPORATION8.04%53 184
EDWARDS LIFESCIENCES CORPORATION47.77%47 072